239 related articles for article (PubMed ID: 7980801)
21. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
24. Sample-size calculations for trials that inform individual treatment decisions: a 'true-choice' approach.
Girling AJ; Lilford RJ; Braunholtz DA; Gillett WR
Clin Trials; 2007; 4(1):15-24. PubMed ID: 17327242
[TBL] [Abstract][Full Text] [Related]
25. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
Liu J; Lin Y; Shih WJ
Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
[TBL] [Abstract][Full Text] [Related]
26. A type of sample size design in cancer clinical trials for response rate estimation.
Liu J
Contemp Clin Trials; 2011 Jan; 32(1):140-6. PubMed ID: 20965278
[TBL] [Abstract][Full Text] [Related]
27. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
28. A bayesian approach to the design of phase II clinical trials.
Sylvester RJ
Biometrics; 1988 Sep; 44(3):823-36. PubMed ID: 3203131
[TBL] [Abstract][Full Text] [Related]
29. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
30. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
31. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
32. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
33. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
34. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
35. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
Heitjan DF; Li H
Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
[TBL] [Abstract][Full Text] [Related]
36. The sample size for a clinical trial: a Bayesian-decision theoretic approach.
Halpern J; Brown BW; Hornberger J
Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007
[TBL] [Abstract][Full Text] [Related]
37. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti P; Gubbiotti S; Sambucini V
Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
[TBL] [Abstract][Full Text] [Related]
38. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
39. Use of predictive probabilities in phase II and phase III clinical trials.
Johns D; Andersen JS
J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
[TBL] [Abstract][Full Text] [Related]
40. Bayesian design and analysis of two x two factorial clinical trials.
Simon R; Freedman LS
Biometrics; 1997 Jun; 53(2):456-64. PubMed ID: 9192445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
